Alvogen

Alvogen is a private, US-based generics and specialty pharma company founded in 2009, headquartered in Parsippany, New Jersey. It operates through distinct business units for generics (Alvogen), brand products (Almatica), injectables (Almaject), and US manufacturing (Norwich). The company's strategy centers on building a targeted portfolio of complex products, leveraging partnerships, and maintaining a lean operational structure to bring affordable medicines to market. A recent major transaction was the 2024 sale of its international business to Lotus, creating a leading international specialized generics platform.

Integrated development and manufacturing platform for complex generics and 505(b)(2) products, with expertise in complex inhalation, injectables, and transdermal systems, driven by in-licensing and partnerships.

Alvogen competes in the crowded US generics market against large players like Teva, Viatris, and Sun Pharma, as well as other focused complex generics companies such as Hikma, Amphastar, and Lannett. Its differentiation relies on a lean, partnership-driven model targeting high-barrier, complex products.